PMID- 38033836
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231202
IS  - 2251-6093 (Electronic)
IS  - 2251-6085 (Print)
IS  - 2251-6085 (Linking)
VI  - 52
IP  - 9
DP  - 2023 Sep
TI  - Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with 
      or without Systemic Sclerosis: A Meta-Analysis.
PG  - 1781-1787
LID - 10.18502/ijph.v52i9.13561 [doi]
AB  - BACKGROUND: Nintedanib is a potent intracellular inhibitor of tyrosine kinases 
      and modulates the pathways involved in the development of fibrosis. We assessed 
      nintedanib efficacy and safety in interstitial lung disease (ILD) patients. 
      METHODS: We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register 
      to identify available articles (up to April 2022). We conducted a meta-analysis 
      of randomized controlled trials (RCTs) examining nintedanib efficacy and safety 
      in patients with ILD with or without systemic sclerosis (SSc). RESULTS: 
      Meta-analysis of five RCTs including 2,470 patients with ILD (1,343 nintedanib 
      group and 1,127 controls) revealed that the annual rate of change in forced vital 
      capacity (FVC) was significantly lower in the ILD group than in the control group 
      (standardized mean difference [SMD] = 0.336; 95% confidence interval (CI) = 
      0.256-0.416, P<0.001). Stratification by disease type showed a low annual rate of 
      change in FVC in patients with and without SSc (SMD = 0.389, 95% CI=0.294-0.478, 
      P<0.001; SMD=0.177, 95% CI=0.013-0.340, P<0.00). The incidence of serious adverse 
      events did not differ between the nintedanib and placebo groups; however, adverse 
      events (AEs) and withdrawals due to AEs were significantly higher in the 
      nintedanib group than in the placebo group (SMD =2.365, 95% CI=1.673-3.343, 
      P<0.001; SMD =1.740, 95% CI= 1.385-2.185, P<0.001). CONCLUSION: Nintedanib is 
      effective for ILD with or without SSc. However, it increased the incidence of AEs 
      and withdrawals due to AEs.
CI  - Copyright(c) 2023 Lee et al. Published by Tehran University of Medical Sciences.
FAU - Lee, Young Ho
AU  - Lee YH
AD  - Department of Rheumatology, Korea University College of Medicine, Seoul, Korea.
FAU - Song, Gwan Gyu
AU  - Song GG
AD  - Department of Rheumatology, Korea University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Iran J Public Health
JT  - Iranian journal of public health
JID - 7505531
PMC - PMC10682577
OTO - NOTNLM
OT  - Efficacy
OT  - Interstitial lung disease
OT  - Nintedanib
OT  - Safety
EDAT- 2023/11/30 18:45
MHDA- 2023/11/30 18:46
PMCR- 2023/09/01
CRDT- 2023/11/30 17:24
PHST- 2022/07/20 00:00 [received]
PHST- 2022/10/18 00:00 [accepted]
PHST- 2023/11/30 18:46 [medline]
PHST- 2023/11/30 18:45 [pubmed]
PHST- 2023/11/30 17:24 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - IJPH-52-1781 [pii]
AID - 10.18502/ijph.v52i9.13561 [doi]
PST - ppublish
SO  - Iran J Public Health. 2023 Sep;52(9):1781-1787. doi: 10.18502/ijph.v52i9.13561.